Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc. (DRMA) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · DRMA · as of Sep 30, 2025
Ownership Breakdown
5
Institutional Holders
▼ 5 vs Q2
$463,005
Total Inst. Value
▲ $165,506 vs Q2
681,557
Shares Outstanding
freeFloat 73.15%
92,232
13F Shares Held
▼ 415,922 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
DRMA largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
ARMISTICE CAPITAL, LLC pharmaceutical preparations | 81.7K | 7.95% | 7.95% | $409.90M | Nov 17, 2025 | NEW |
UBS GROUP AG pharmaceutical preparations | 10.0K | 97.88% | 97.88% | $50.44M | Nov 13, 2025 | NEW |
TOWER RESEARCH CAPITAL LLC (TRC) pharmaceutical preparations | 426 | 4.15% | 4.15% | $2.14M | Nov 14, 2025 | NEW |
SBI SECURITIES CO., LTD. pharmaceutical preparations | 101 | 0.98% | 0.98% | $507,000 | Nov 5, 2025 | NEW |
BANK OF AMERICA CORP /DE/ pharmaceutical preparations | 4 | 0.04% | 0.04% | $20,000 | Feb 3, 2026 | NEW |
TWO SIGMA SECURITIES, LLC pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Nov 14, 2025 | EXIT |
TOWER RESEARCH CAPITAL LLC (TRC) pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Nov 14, 2025 | EXIT |
CITIGROUP INC pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Nov 10, 2025 | EXIT |
ARMISTICE CAPITAL, LLC pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Nov 17, 2025 | EXIT |
JONES FINANCIAL COMPANIES LLLP pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Nov 4, 2025 | EXIT |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
0
Increased
+0 shares5
New Positions
first time holders0
Decreased
−0 shares10
Sold Out
fully exitedNet shares change (top 50)
+0
+0 / −0
Net new holders
-5
5 new / 10 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
DRMA insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
19
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Bedoya-Toro Munera Maria E SVP, Regulatory Affairs | Feb 17, 2026 | Purchase | 1,000 | $1.27 | $1.3K | 1.0K | Form 4 ↗ |
PROEHL GERALD T President, CEO and Chairman | Jan 2, 2026 | Award | 37,500 | $2.18 | $81.8K | 37.5K | Form 4 ↗ |
HALE DAVID F director | Jan 2, 2026 | Award | 2,500 | $2.18 | $5.5K | 2.5K | Form 4 ↗ |
WIERENGA WENDELL director | Jan 2, 2026 | Award | 2,500 | $2.18 | $5.5K | 2.5K | Form 4 ↗ |
Bedoya-Toro Munera Maria E SVP, Regulatory Affairs | Jan 2, 2026 | Award | 9,000 | $2.18 | $19.6K | 9.0K | Form 4 ↗ |
Scott Kathleen D. director | Jan 2, 2026 | Award | 2,500 | $2.18 | $5.5K | 2.5K | Form 4 ↗ |
Nardo Christopher J. Senior VP, CDO | Jan 2, 2026 | Award | 18,000 | $2.18 | $39.2K | 18.0K | Form 4 ↗ |
Sandler Andrew Seth director | Jan 2, 2026 | Award | 2,500 | $2.18 | $5.5K | 2.5K | Form 4 ↗ |
Van Hoose Kyri K. SVP, CFO | Jan 2, 2026 | Award | 18,000 | $2.18 | $39.2K | 18.0K | Form 4 ↗ |
Mento Steven J director | Jan 2, 2026 | Award | 2,500 | $2.18 | $5.5K | 2.5K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Dermata Therapeutics, Inc. (DRMA) is primarily owned by institutional investors, who hold approximately 13.5% of total shares outstanding. Company insiders own approximately 26.85%, while retail and public investors account for the remaining 59.61%.
The largest institutional shareholder of Dermata Therapeutics, Inc. is ARMISTICE CAPITAL, LLC, holding approximately 81,654 shares — equal to 7.95% of outstanding shares — as of September 30, 2025.
A total of 5 institutional investors currently hold DRMA stock, with a combined institutional value of approximately $463,005 as of the most recent 13F filing period.
Frequently asked questions
DRMA ownershipDermata Therapeutics, Inc. (DRMA) is primarily owned by institutional investors, who hold approximately 13.5% of shares. The largest shareholder is ARMISTICE CAPITAL, LLC with a 7.95% stake. Company insiders hold 26.85%. Data sourced from SEC Form 13F as of September 30, 2025.